AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising ...

Made in Chelsea star Louise Thompson nearly died while giving birth to Leo, her first child with fiancé Ryan Libbey in ...

The great news is that AbbVie has seemingly done that with its new immunology drugs Rinvoq and Skyrizi. These drugs have seen enough success that management has raised their long-term growth ...